Wall Street brokerages expect Osmotica Pharmaceuticals PLC (NASDAQ:OSMT) to report earnings per share of ($0.03) for the current quarter, according to Zacks. Two analysts have made estimates for Osmotica Pharmaceuticals’ earnings. Osmotica Pharmaceuticals posted earnings of ($4.99) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 99.4%. The business is expected to announce its next earnings report on Thursday, November 14th.
On average, analysts expect that Osmotica Pharmaceuticals will report full year earnings of ($0.25) per share for the current fiscal year. For the next year, analysts expect that the firm will report earnings of ($0.12) per share, with EPS estimates ranging from ($0.18) to ($0.06). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow Osmotica Pharmaceuticals.
Osmotica Pharmaceuticals (NASDAQ:OSMT) last issued its quarterly earnings data on Thursday, August 8th. The company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.04) by $0.06. Osmotica Pharmaceuticals had a negative return on equity of 32.14% and a negative net margin of 97.91%. The company had revenue of $57.53 million for the quarter, compared to analyst estimates of $57.90 million.
OSMT has been the topic of a number of research analyst reports. Zacks Investment Research raised Osmotica Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, July 16th. Barclays initiated coverage on Osmotica Pharmaceuticals in a research note on Tuesday, June 11th. They issued an “overweight” rating and a $11.00 price target on the stock. ValuEngine raised Osmotica Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Wells Fargo & Co reiterated a “buy” rating on shares of Osmotica Pharmaceuticals in a research report on Friday, August 9th. Finally, Jefferies Financial Group set a $10.00 price objective on Osmotica Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, August 12th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $13.00.
A number of large investors have recently bought and sold shares of the business. Sofinnova Investments Inc. raised its position in Osmotica Pharmaceuticals by 107.5% in the second quarter. Sofinnova Investments Inc. now owns 525,198 shares of the company’s stock valued at $1,996,000 after purchasing an additional 272,109 shares during the period. BlackRock Inc. acquired a new stake in shares of Osmotica Pharmaceuticals in the fourth quarter valued at $3,682,000. Millennium Management LLC acquired a new stake in shares of Osmotica Pharmaceuticals in the fourth quarter valued at $2,568,000. Northern Trust Corp grew its stake in shares of Osmotica Pharmaceuticals by 5.6% in the second quarter. Northern Trust Corp now owns 99,449 shares of the company’s stock valued at $378,000 after buying an additional 5,230 shares in the last quarter. Finally, Geode Capital Management LLC acquired a new stake in shares of Osmotica Pharmaceuticals in the fourth quarter valued at $668,000. Institutional investors own 12.36% of the company’s stock.
Shares of NASDAQ:OSMT traded up $0.10 during trading on Wednesday, reaching $3.10. The stock had a trading volume of 1,128 shares, compared to its average volume of 56,993. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.41 and a current ratio of 1.78. The business has a fifty day moving average price of $3.46 and a 200-day moving average price of $4.46. The stock has a market cap of $148.90 million and a PE ratio of -6.08. Osmotica Pharmaceuticals has a 1-year low of $2.20 and a 1-year high of $9.90.
Osmotica Pharmaceuticals Company Profile
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms.
Featured Story: What are no-load funds?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.